RECENT PATENTS ON SOLID DISPERSIONS OF ANTIHYPERLIPIDEMIC DRUGS

Authors

  • PRITAM SINGH Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, India
  • ARUN NANDA MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana (India)-133207

DOI:

https://doi.org/10.22159/ijap.2023v15i2.42402

Keywords:

Solid Dispersions, Patents, Antihyperlipidemic drugs

Abstract

Hyperlipidemia is a worsening health condition in developed and developing countries, especially among the younger generation due to their lifestyle. The World Health Organization reported 2.6 million deaths globally due to hyperlipidemia. Therefore, there is a huge demand of antihyperlipidemic drugs in the pharmaceutical market. Approximately 60% of the total active drug content used in hyperlipidemia suffer from poor water solubility, particularly BCS class II drugs. Poor water solubility may result in insufficient absorption and finally affects the bioavailability of the drug causes ineffectiveness in lowering lipid profile of patients. In recent years, solid dispersion technology has proved to be a simple, effective and economical approach for industrial application to increase the solubility of these drugs. This review paper is an attempt to compile up various research as well as patents reports related to solid dispersions of poor water soluble antihyperlipidemic drugs.

Downloads

Download data is not yet available.

References

Global Health Observatory data. World health Organization Updates. WHO updates; 2015. Available from: http://www.who.int/gho/ncd/risk_factors/cholesterol_text/en/. [Last accessed on 28 Apr 2020]

Pan J, Ren Z, Li W, Wei Z, Rao H, Ren H. Prevalence of hyperlipidemia in shanxi province, china and application of bayesian networks to analyse its related factors. Sci Rep. 2018;8(1):3750. doi: 10.1038/s41598-018-22167-2, PMID 29491353.

Center of Disease Control and prevention. National Center for Health Statistics; 2018. Available from: http://www.cdc.gov/nchs/fastats/cholesterol.htm [Last accessed on 28 Apr 2020]

Gupta A, Sehgal V, Mehan S. Hyperlipidemia: an updated review. Int J Biopharm Toxicol Res. 2011;1(1):81-9.

Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20. doi: 10.1023/a:1016212804288, PMID 7617530.

Gardner D. The intelisite capsule: a new easy to use approach for assessing regional drug absorption from gastrointestinal tract. Pharm Technol Eur. 1997;9:46-53.

Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006;6(5):501-8. doi: 10.1016/j.coph.2006.04.007, PMID 16890020.

Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315-499. doi: 10.1124/pr.112.005660, PMID 23383426.

Sun J, Wang F, Sui Y, She Z, Zhai W, Wang C. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. Int J Nanomedicine. 2012;7:5733-44. doi: 10.2147/IJN.S34365. PMID 23166438.

Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59(7):617-30. doi: 10.1016/j.addr.2007.05.011, PMID 17597252.

Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007;59(7):603-16. doi: 10.1016/j.addr.2007.05.010, PMID 17619064.

Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329(1-2):1-11. doi: 10.1016/j.ijpharm.2006.10.044, PMID 17137734.

Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. i. a comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull. 1961;9(11):866-72. doi: 10.1248/cpb.9.866.

Levy G. Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. Am J Pharm Sci Support Public Health. 1963;135:78-92. PMID 13930259.

Kanig JL. Properties of fused mannitol in compressed tablets. J Pharm Sci. 1964;53(2):188-92. doi: 10.1002/jps.2600530217, PMID 14123962.

Goldberg AH, Gibaldi M, Kanig JL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. I. Theoretical considerations and discussion of the literature. J Pharm Sci. 1965;54(8):1145-8. doi: 10.1002/jps.2600540810, PMID 5882218.

Bates TR. Dissolution characteristics of reserpine-polyvinylpyrrolidone co-precipitates. J Pharm Pharmacol. 1969;21(10):710-2. doi: 10.1111/j.2042-7158.1969.tb08159.x, PMID 4390622.

Simonelli AP, Mehta SC, Higuchi WI. Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci. 1969;58(5):538-49. doi: 10.1002/jps.2600580503, PMID 5796439.

Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60(9):1281-302. doi: 10.1002/jps.2600600902, PMID 4935981.

Haque MA, Hasan MF, Dewan I, Islam SMA, Bhuiyan MA. Studies to improve dissolution properties of poorly soluble carbamazipine by solid dispersion. Bangladesh Pharm J. 2012;15(1):73-7.

Moneghini M, Zingone G, De Zordi ND. Influence of the microwave technology on the physical–chemical properties of solid dispersion with nimesulide. Powder Technol. 2009;195(3):259-63. doi: 10.1016/j.powtec.2009.06.006.

Otsuka M, Maeno Y, Fukami T, Inoue M, Tagami T, Ozeki T. Solid dispersions of efonidipine hydrochloride ethanolate with improved physicochemical and pharmacokinetic properties prepared with microwave treatment. Eur J Pharm Biopharm. 2016;108:25-31. doi: 10.1016/j.ejpb.2016.08.008, PMID 27553261.

Isaac J, Kaity S, Ganguly S, Ghosh A. Microwave-induced solid dispersion technology to improve bioavailability of glipizide. J Pharm Pharmacol. 2013;65(2):219-29. doi: 10.1111/j.2042-7158.2012.01595.x, PMID 23278689.

Hasegawa S, Hamaura T, Furuyama N, Kusai A, Yonemochi E, Terada K. Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method. Int J Pharm. 2005;302(1-2):103-12. doi: 10.1016/j.ijpharm.2005.06.021, PMID 16102926.

Jones DS, Margetson DN, Mcallister MS, Yu T, Shu L, Mccoy CP. Thermodynamically stable amorphous drug dispersions in amorphous hydrophilic polymers engineered by hot melt extrusion. Chem Eng Res Des. 2014;92(12):3046-54. doi: 10.1016/j.cherd.2014.08.022.

El-Badry ME, Fetih G, Fathy M. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50/13 and PEG4000. Saudi Pharm J. 2009;17(3):217-25. doi: 10.1016/j.jsps.2009.08.006, PMID 23964164.

Khodaverdi E, Khalili N, Zangiabadi F, Homayouni A. Preparation, characterization and stability studies of glassy solid dispersions of indomethacin using PVP and isomalt as carriers. Iran J Basic Med Sci. 2012;15(3):820-32. PMID 23493157.

Mogal SA, Gurjar PN, Yamgar DS, Kamod AC. Solid dispersion technique for improving solubility of some poorly soluble drugs. Pharm Lett. 2012;4(5):1574-86.

Kim KH, Hwang SJ, Hwang JS, Pai MC. Solid dispersion comprising tacrolimus and method for preparing the same. WIPO Patent no. WO2013036053A2. Samyang Biopharmaceuticals Corporation; 2013.

Uramatsu S, Kida A, Shinike H, Uemura T, Fukumori Y. Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion. U.S Patent no. US9. Nisshin Kasei KK, Daido. Chemical Publishing Corporation; 2015. Vol. 101(617) B2.

Verhoeven E, De Beer TR, Schacht E, Van den Mooter G, Remon JP, Vervaet C. Influence of polyethylene glycol/polyethylene oxide on the release characteristics of sustained-release ethylcellulose mini-matrices produced by hot-melt extrusion: in vitro and in vivo evaluations. Eur J Pharm Biopharm. 2009;72(2):463-70. doi: 10.1016/j.ejpb.2009.01.006, PMID 19462482.

Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev Ind Pharm. 2007;33(9):909-26. doi: 10.1080/03639040701498759, PMID 17891577.

Forster A, Hempenstall J, Rades T. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J Pharm Pharmacol. 2001;53(3):303-15. doi: 10.1211/0022357011775532, PMID 11291745.

Liu J, Cao F, Zhang C, Ping Q. Use of polymer combinations in the preparation of solid dispersions of a thermally unstable drug by hot-melt extrusion. Acta Pharm Sin B. 2013;3(4):263-72. doi: 10.1016/j.apsb.2013.06.007.

Li M, Ioannidis N, Gogos C, Bilgili E. A comparative assessment of nanocomposites vs. amorphous solid dispersions prepared via nanoextrusion for drug dissolution enhancement. Eur J Pharm Biopharm. 2017;119:68-80. doi: 10.1016/j.ejpb.2017.06.003, PMID 28583589.

Chuanbin W, Ming L, Yan G. Diflunisal solid dispersion and preparation method thereof. China Patent no. CN103202811A. Guangzhou, China: Sun Yat-Sen University; 2015.

Ford JL, Rubinstein MH. Preparation, properties and ageing of tablets prepared from the chlorpropamide-urea solid dispersion. Int J Pharm. 1981;8(4):311-22. doi: 10.1016/0378-5173(81)90071-5.

Seo A, Holm P, Kristensen HG, Schaefer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. Int J Pharm. 2003;259(1-2):161-71. doi: 10.1016/s0378-5173(03)00228-x, PMID 12787644.

Vilhelmsen T, Eliasen H, Schaefer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. Int J Pharm. 2005;303(1-2):132-42. doi: 10.1016/j.ijpharm.2005.07.012, PMID 16139973.

Helle E. Method for preparation of an agglomerate using melt agglomeration. WIPO Patent no. WO/2004073687. H Lundbeck, A/S; 2004.

Wu JX, Yang M, Berg Fv, Pajander J, Rades T, Rantanen J. Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. Eur J Pharm Sci. 2011;44(5):610-20. doi: 10.1016/j.ejps.2011.10.008, PMID 22024381.

Kulkarni SK, Dalal SK, Jahagirdar AH. Solid dispersion of Rifaximin. Patent no. EP2493456B1.

Dong Z, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm. 2008;355(1-2):141-9. doi: 10.1016/j.ijpharm.2007.12.017, PMID 18243605.

Duarte I, Gasper F, Pereira R, Temtem M, Vicente J. A method of preparing amorphous solid dispersion in submicron range by co-precipitation. Australian Patent no. AU2015295073B2. Hovione International Ltd.; 2019.

Cal K, Sollohub K. Spray drying technique. I: Hardware and process parameters. J Pharm Sci. 2010;99(2):575-86. doi: 10.1002/jps.21886, PMID 19774644.

Sollohub K, Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci. 2010;99(2):587-97. doi: 10.1002/jps.21963, PMID 19862804.

Broadhead J, Edmond Rouan SKE, Rhodes CT. The spray drying of pharmaceuticals. Drug Dev Ind Pharm. 1992;18(11-12):1169-206. doi: 10.3109/03639049209046327.

Beyerinck RA, Deibele HLM, Dobry DE, Ray RJ, Settell DM, Spence KR. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus. U.S Patent no. US 9,339. Bend research. Inc. 2016. p. 467 B2.

Van Drooge DJV, Hinrichs WLJ, Visser MR, Frijlink HW. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int J Pharm. 2006;310(1-2):220-9. doi: 10.1016/j.ijpharm.2005.12.007, PMID 16427226.

Brynjelsen S, Doty M, Kipp JE, Jayswal N, Narayanan K. Preparation of submicron sized nanoparticles via dispersion lyophilization. US patent no. US 8722091B2. Baxter International Inc; 2014.

Liu D, Wang F, Wang D, Li S, Chen J, Xu H. Silibinin-ursodesoxycholic acid solid dispersoid and preparation method thereof. China Patent no. CN103191439B. China: Shenyang Pharmaceutical University; 2014.

Zhang X, Sun N, Wu B, Lu Y, Guan TZ, Wu W. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique. Powder Technol. 2008;182(3):480-5. doi: 10.1016/j.powtec.2007.07.011.

Hoshino T, Kusaki F, Fukui I. Solid dispersion preparation. US Patent no. US20070248681 A1. Shin Etsu Chemical Co. Ltd.; 2013.

Rogers TL, Hu J, Yu Z, Johnston KP, Williams RO. A novel particle engineering technology: spray-freezing into liquid. Int J Pharm. 2002;242(1-2):93-100. doi: 10.1016/s0378-5173(02)00154-0, PMID 12176230.

Briggs AR, Maxwell TJ. Process for preparing powder blends. U.S Patent no. US3721725A. E I Du Pont de Nemours and Co.; 1973.

Zhang D, Yang Y, Zhang S. A kind of tanshinone IIA hydroxyapatite solid dispersions and preparation method thereof. China Patent no. CN107375219A. Qinghai colorful flower Biological Technology Co., Ltd.; 2019.

Nagy ZK, Balogh A, Demuth B, Pataki H, Vigh T, Szabo B, Molnar K, Schmidt B, Horak P, Marosi G, Verreck G, Assche I, Brewster M. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole. Int J Pharm. 2015;480(1-2):137-42. doi: 10.1016/j.ijpharm.2015.01.025, PMID 25596415.

Deitzel JM, Kleinmeyer J, Harris D, Beck Tan NCB. The effect of processing variables on the morphology of electrospun nanofibers and textiles. Polymer. 2001;42(1):261-72. doi: 10.1016/S0032-3861(00)00250-0.

Zhang W, Yan E, Huang Z, Wang C, Xin Y, Zhao Q, Tong Y. Preparation and study of PPV/PVA nanofibers via electrospinning PPV precursor alcohol solution. European Polymer Journal. 2007;43(3):802-807. doi: 10.1016/j.eurpolymj.2006.11.015.

Dengguang Y, Xia W, Xiaoyan L, Ying L, wei Q. Preparation method for nano-granular solid dispersion of hydrophobic drug by high-voltage electrostatic spraying. China Patent Nno. CN102218019B. Shanghai University of Science and Technology; 2013.

Limin Z, Dengguang Y, Xia S, Zhang X, Wei XN. Method for preparing hydrophobic drug nanofibre felty solid dispersion by high-voltage electrostatic spinning. China Patent no. CN 101664380A. Donghua University; 2010.

Riekes MK, Caon T, Jr JS, Sordi R, Kuminek G, Bernardi LS, Rambo CR, Campos CEM, Fernandes D, Stulzer HK. Enhanced hypotensive effect of nimodipine solid dispersions produced by supercritical CO2 drying. Powder Technology. 2015;278:204-10.

Li C, Li ZM, Zhaojie JM. Berberine-sodium caprate solid dispersion and application of same in treating diabetes and complications thereof. China Patent no. CN104069066A. Jilin University; 2017.

R Kumari, P Chandel, A Kapoor. Paramount role of solid dispersion in enhancement of solubility. Indo Glob J Pharm Sci. 2013;3(1):78-89. doi: 10.35652/IGJPS.2013.10.

Wu K, Li J, Wang W, Winstead DA. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J Pharm Sci. 2009;98(7):2422-31. doi: 10.1002/jps.21598, PMID 18972575.

Liuchen ML, Lin PY, Mingfa FF. Cyclosporin a dispersion solid and its preparation method. China Patent no. CN1559606A. Fudan University, Taishan Cchemical. Pharmaceutical Press Co., Ltd.; 2006.

Branham ML, Moyo T, Govender T. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. Eur J Pharm Biopharm. 2012;80(1):194-202. doi: 10.1016/j.ejpb.2011.08.005, PMID 21906676.

Nart V, França MT, Anzilaggo D, Riekes MK, Kratz JM, de Campos CE, Simoes CM, Stulzer HK. Ball-milled solid dispersions of BCS Class IV drugs: impact on the dissolution rate and intestinal permeability of acyclovir. Mater Sci Eng C Mater Biol Appl. 2015;53:229-38. doi: 10.1016/j.msec.2015.04.028, PMID 26042711.

Bashiri Shahroodi A, Nassab PR, Szabo Revesz P, Rajko R. Preparation of a solid dispersion by a dropping method to improve the rate of dissolution of meloxicam. Drug Dev Ind Pharm. 2008;34(7):781-8. doi: 10.1080/03639040801925735, PMID 18612916.

Kalia A, Poddar M. Solid dispersions: an approach towards enhancing dissolution rate. Int J Pharm Pharm Sci. 2011;3(4):9-19.

Ambike AA, Mahadik KR, Paradkar A. Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm Res. 2005;22(6):990-8. doi: 10.1007/s11095-005-4594-z, PMID 15948043.

Thybo P, Pedersen BL, Hovgaard L, Holm R, Mullertz A. Characterization and physical stability of spray dried solid dispersions of probucol and PVP-K30. Pharm Dev Technol. 2008;13(5):375-86. doi: 10.1080/10837450802244843, PMID 18720236.

Srinarong P, Faber JH, Visser MR, Hinrichs WLJ, Frijlink HW. Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. Eur J Pharm Biopharm. 2009;73(1):154-61. doi: 10.1016/j.ejpb.2009.05.006, PMID 19465121.

He H, Yang R, Tang X. In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev Ind Pharm. 2010;36(6):681-7. doi: 10.3109/03639040903449720, PMID 20136483.

Yang L, Shao Y, Han HK. Development of omega-3 phospholipid-based solid dispersion of fenofibrate for the enhancement of oral bioavailability. Eur J Pharm Sci. 2015;78:103-10. doi: 10.1016/j.ejps.2015.07.007, PMID 26165620.

Patel M, Tekade A, Gattani S, Surana S. Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques. AAPS PharmSciTech. 2008;9(4):1262-9. doi: 10.1208/s12249-008-9171-4, PMID 19115112.

Li J, Di L, Cheng X, Ji W, Piao H, Cheng G. The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. Xenobiotica. 2020;50(5):593-601. doi: 10.1080/00498254.2019.1662136, PMID 31505985.

Kim MS, Kim JS, Cho W, Park HJ, Hwang SJ. Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers. Int J Biol Macromol. 2013;59:138-42. doi: 10.1016/j.ijbiomac.2013.03.068, PMID 23567288.

Jahangiri A, Barzegar Jalali M, Garjani A, Javadzadeh YJ, Hamishehkar H, Afroozian A, Adibkia K. Pharmacological and histological examination of atorvastatin-PVP K30 solid dispersions. Powder Technology. 2015;286:538-45. doi: 10.1016/j.powtec.2015.08.047.

Jahangiri A, Barzegar Jalali M, Javadzadeh YJ, Hamishehkar H, Adibkia K. Physicochemical characterization of atorvastatin calcium/ezetimibe amorphous nano-solid dispersions prepared by electrospraying method. Artif Cells Nanomed Biotechnol. 2017;45(6):11451-8. doi: 10.1080/21691401.2016.1202262, PMID 27406894.

Hussain T, Waters LJ, Parkes GMB, Shahzad Y. Microwave processed solid dispersions for enhanced dissolution of gemfibrozil using non-ordered mesoporous silica. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2017;520:428-35. doi: 10.1016/j.colsurfa.2017.02.007.

Szuts A, Lang P, Ambrus R, Kiss L, Deli MA, Szabo Revesz P. Applicability of sucrose laurate as surfactant in solid dispersions prepared by melt technology. Int J Pharm. 2011;410(1-2):107-10. doi: 10.1016/j.ijpharm.2011.03.033, PMID 21421029.

Higashi K, Seo A, Egami K, Otsuka N, Limwikrant W, Yamamoto K, Moribe K. Mechanistic insight into the dramatic improvement of pProbucol dissolution in neutral solutions by solid dispersion in Eudragit E PO with saccharin. J Pharm Pharmacol. 2016;68(5):655-64. doi: 10.1111/jphp.12469, PMID 26272472.

Kubo Y, Terashima Y, Yagi N, Nochi H, Tamoto K, Sekikawa H. Enhanced bioavailability of Probucol following the administration of solid dispersion systems of probucol–polyvinylpyrrolidone in rabbits. Biol Pharm Bull. 2009;32(11):1880-4. doi: 10.1248/bpb.32.1880, PMID 19881302.

Kubo Y, Yagi N, Sekikawa H. Stability of probucol-polyvinylpyrrolidone solid dispersion systems. Yakugaku Zasshi. 2011;131(4):629-34. doi: 10.1248/yakushi.131.629, PMID 21467803.

Karolewicz B, Gajda M, Pluta J, Gorniak A. The effect of pluronic F127 on the physicochemical properties and dissolution profile of lovastatin solid dispersions. Journal of Thermal Analysis and Calorimetry. 2016;123(3):2283-90. doi: 10.1007/s10973-015-4935-z.

Górniak A, Gajda M, Pluta J, Czapor Irzabek H, Karolewicz B. Thermal, spectroscopic and dissolution studies of lovastatin solid dispersions with acetylsalicylic acid. Journal of Thermal Analysis and Calorimetry. 2016;125(2):777-84. doi: 10.1007/s10973-016-5279-z.

Karolewicz B, Gajda M, Pluta J, Gorniak A. Dissolution study and thermal analysis of fenofibrate–pluronic F127 solid dispersions. Journal of Thermal Analysis and Calorimetry. 2016;125(2):751-57. doi: 10.1007/s10973-015-5013-2.

Yang B, Wei C, Qian F, Li S. Surface wettability modulated by surfactant and its effects on the drug release and absorption of fenofibrate solid dispersions. AAPS PharmSciTech. 2019;20(6):234. doi: 10.1208/s12249-019-1446-4, PMID 31236817.

Yang B, Wu L, Ke J, Zhou L, Chen M, Li S, Feng X. Effects of polymer/surfactant as carriers on the solubility and dissolution of fenofibrate solid dispersion. AAPS PharmSciTech. 2019;20(3):102. doi: 10.1208/s12249-018-1273-z, PMID 30723877.

Yousaf AM, Kim DW, Kim JO, Pahn-Shick C, Hyung HB, Lim SJ, Cho KH, Chul SJ, Choi HG, Yousaf A, Kim D, Kim J, Chang P, Baek H, Lim S. Characterization of physicochemical properties of spray-dried solid dispersions loaded with unmodified crystalline fenofibrate. Current Pharmaceutical Analysis. 2015;11(2):139-44. doi: 10.2174/1573412910666141110223457.

Zhang M, Li H, Lang B, O’Donnell K, Zhang H, Wang Z, Dong Y, Wu C, O WilliamsIII. Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing. Eur J Pharm Biopharm. 2012;82(3):534-44. doi: 10.1016/j.ejpb.2012.06.016, PMID 22974985.

Rodde MS, Divase GT, Devkar TB, Tekade AR. Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: in vitro, ex vivo, and in vivo studies. BioMed Res Int. 2014;2014:463895. doi: 10.1155/2014/463895, PMID 24995297/.

Jahan R, Islam MS, Tanwir A, Chowdhury JA. In vitro dissolution study of atorvastatin binary solid dispersion. J Adv Pharm Technol Res. 2013;4(1):18-24. doi: 10.4103/2231-4040.107496, PMID 23662278.

Panghal D, Nagpal M, Thakur GS, Arora S. Dissolution improvement of atorvastatin calcium using modified locust bean gum by the solid dispersion technique. Sci Pharm. 2014;82(1):177-91. doi: 10.3797/scipharm.1301-23, PMID 24634850.

Rao M, Mandage Y, Kaushik T, Thanki K, Bhise SD. Dissolution improvement of simvastatin by surface solid dispersion technology. Dissolution Technol. 2010;17(2):27-34. doi: 10.14227/DT170210P27.

Tapas A, Ingle V, Kawtikwar P, Sakarkar D. Enhanced dissolution profile and antihyperlipedimic activity of simvastatin by solid dispersion with pluronic F68. Drug Delivery Letters. 2013;3(2):101-9. doi: 10.2174/2210303111303020003.

Choudhary A, Rana AC, Aggarwal G, Kumar V, Zakir F. Development and characterization of an atorvastatin solid dispersion formulation using skimmed milk for improved oral bioavailability. Acta Pharmaceutica Sinica B. 2012;2(4):421-8. doi: 10.1016/j.apsb.2012.05.002.

Salmani JM, Lv H, Asghar S, Zhou J. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin. Pharm Dev Technol. 2015;20(4):465-72. doi: 10.3109/10837450.2014.882938, PMID 24490758.

Javeer SD, Patole R, Amin P. Enhanced solubility and dissolution of simvastatin by HPMC-based solid dispersions prepared by hot melt extrusion and spray-drying method. Journal of Pharmaceutical Investigation. 2013;43(6):471-80. doi: 10.1007/s40005-013-0092-1.

Yin L, Maya MAS, Gillaud SJ, Schmidt RL. The cellulose ether being esterified with dicarboxylic acids. China Patent no. CN105164162B. Dow Global Technology Co., Ltd., University of Minnesota Board of Trustees; 2017.

Naval TS, Bates JMDFS, Reinek TM. Sugar containing amphipathic copolymer, China Patent no. CN105308081B. University of Minnesota; 2017.

Lei W, Lei C. Atorvastatin calcium tablet and preparation method thereof, China Patent no. CN104306343A. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.; 2017.

Guimin Z, Fanliang M, Jipeng H. Atorvastatin calcium tablet. China Patent no. CN104546775A. Shandong New Times Pharmaceutical Co., Ltd.; 2017.

Lei W, Lei C. A kind of atorvastatin agent and preparation method thereof. China Patent no. CN104306343B. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.; 2017.

Yanlong Q, Weiping Z, Hua B. Method for preparing rosuvastatin calcium tablet solid dispersion. China Patent no. CN103690504A. Beijing Huaxi United Technology Development Co., Ltd.; 2018.

Guoxin S, Yi H. Rosuvastatin calcium capsule and preparation method thereof. China Patent no. CN105147636A. Shanghai Taohong Chemical Technology Co., Ltd.; 2018.

Stamm A, Seth P. Process for producing fenofibrate tablets. US Patent no. US8329214B2. Lab Fournier. SAS Publishing; 2012.

Law D, Krill SL, Schmitt EA, Fort JJ. Formulations comprising lipid-regulating agents. US Patent no. US6465011B2. AbbVie Inc.; 2002.

Guy SH, Kim J, Chi YH. Moon combined preparation containing amlodipine cansylate and simvastatin and method for producing the same. Japan Patent no. JP2009521526A. Hanmi farm. Shio, LTD.; 2009.

Friesen DT, Caspar B, Ketner RJ, Lorenz DA, Lyon DK, Joseph T. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase. US Patent no. US8828438B2. Bend research. Inc.; 2014.

Dennis EH, Joseph PAZ, Samuel NKP, Ying T, Kumar SRT. Amorphous tecovirimat preparation. Australia Patent no. AU2014290333B2. Siga Pharmaceuticals Inc.; 2018.

Atluri H, Chong CW, Kuehl R, Shu C, Tay PS, Hulvat JF. Novel formulations of a bruton's tyrosine kinase inhibitor. US Patent US20180028537A1. Pharmacyclics LLC, Patheon Development Services Inc; ; 2018.

Chal B, Nejati E, Pakdaman R, Stefanidis D. Combination formulation of three antiviral compounds. Patent no. US20170360874A1. Gilead Sciences Inc, Gilead Pharmasset LLC; 2017.

Brown B, Chen H, Degoey D, Halvorsen G, Hartune J, Heymen HR. Compositions and methods for treating hcv infection. Patent no. WO2018093717A1. Abbvie Inc; 2017.

Ghosh I, Snyder J, Tong W, Vippagunta S. Method for making solid dispersions of highly crystalline therapeutic compounds. Europe Patent no. EP2054040A2. Novartis Pharma GmbH, Novartis. 2011.

Shah K, Blazey CM. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy] phenyl}-N′-(4-fluor phenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use. WIPO Patent no. WO2018218233A1. Exelixis Inc; 2018.

Published

08-03-2023

How to Cite

SINGH, P., & NANDA, A. (2023). RECENT PATENTS ON SOLID DISPERSIONS OF ANTIHYPERLIPIDEMIC DRUGS. International Journal of Applied Pharmaceutics, 15(2), 23–31. https://doi.org/10.22159/ijap.2023v15i2.42402

Issue

Section

Review Article(s)